Navigation Links
Alseres Pharmaceuticals, Inc. to Present at The Neurotech Industry Investing & Partnering Conference
Date:5/5/2008

HOPKINTON, Mass., May 5 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) today announced that the Company will participate in a panel entitled "Traumatic Brain and Spinal Cord Injury" at the Neurotech Industry Investing & Partnering Conference in Boston, MA, Thursday, May 8, 2008. The session will focus on emerging treatments of major traumatic injuries to the Central Nervous System (CNS). The event is the premier partnering and investing conference for the segment of the healthcare sector focused on neurological technologies.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070608/NEF043LOGO )

About Alseres

Alseres Pharmaceuticals, Inc. (ALSE) is engaged in the development of therapeutic and diagnostic products primarily for disorders in the central nervous system (CNS). The Company maintains a world-class intellectual property position in the field of regenerative therapeutics. The Company's focus is reflected in several important initiatives. CETHRIN, a recombinant- protein-based drug designed to promote nerve repair after acute spinal cord injury, demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease and potentially dementia and ADHD. The Company's lead molecular imaging product candidate is ALTROPANE which is in Phase III clinical trials for the diagnosis of Parkinsonian Syndromes including Parkinson's Disease. The Company has research collaborations with Harvard Medical School and Children's Hospital Boston.

Alseres is a trademark and CETHRIN and ALTROPANE are registered trademarks of Alseres Pharmaceuticals, Inc.

Contact: Sharon Correia -- 508-497-2360 ext 224 scorreia@alseres.com or

Adam Friedman -- 212-981-2529 ext 18 adam@adam-friedman.com

http://www.alseres.com


'/>"/>
SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Alseres Pharmaceuticals, Inc. Complies With NASDAQ Rule Regarding Recently Filed 10-K
2. Alseres Pharmaceuticals, Inc. Raises $5 Million
3. Alseres Pharmaceuticals, Inc. to Present at New York Society of Security Analysts Conference
4. Lotus Pharmaceuticals, Inc. Announces Resignation of Director Mel Rothberg
5. Aida Pharmaceuticals, Inc. Announces Availability of Downloadable Corporate Synopsis on its Website
6. Lotus Pharmaceuticals, Inc. Announces Fourth Quarter and Fiscal Year 2007 Results
7. Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2007 Results
8. Aida Pharmaceuticals, Inc. Announces New Antibiotic Drug Under Development
9. Bayer HealthCare Pharmaceuticals, Amerinet Extend Contrast Media Agreement
10. Barr Pharmaceuticals, Inc. Executive Bios
11. Jazz Pharmaceuticals, Inc. Announces LUVOX CR Launch Plans and Reports Development Pipeline Progress at Investor Day Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... , ... December 07, 2016 , ... ... Medicine will have the unique opportunity to get hands-on experience in an ... school students an immersive experience to gain invaluable, real-life medical skills that are ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... drug in their bodies, a researcher at the Icahn School of Medicine at ... , The study found that when young children are exposed to secondhand marijuana ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... a women growing up with a schizophrenic mother in a unique, personal perspective ... who specializes in treating trauma and addictive disorders at her private psychotherapy practice. ...
(Date:12/7/2016)... ... December 07, 2016 , ... It is vital for any lab to ... analyzed data. The team at Beckman Coulter has designed Kaluza, templates with advanced analytical ... the need to operate in a GLP (Good Laboratory Practice) fashion. , With features ...
(Date:12/7/2016)... ... December 07, 2016 , ... Levels of a protein ... according to a study appearing online in the journal Radiology. , Heart disease and ... increase significantly due to the rapidly aging population. Damage to both organs often occurs ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016  Pennsylvania Physician General ... Drug and Alcohol Programs Gary Tennis ... medications, known as benzodiazepines, developed with the help ... are medications that are frequently prescribed for anxiety ... are used with opioid pain medications, benzodiazepines pose ...
(Date:12/8/2016)... -- A new study by a pair of Geisinger Health ... to treat chronic pain is not only ineffective, it ... including death. Palliative care physicians Mellar ... M.D., authored the study which provides a review of ... was published in the December 2016 edition of Current ...
(Date:12/8/2016)... 2016  EIP Pharma, LLC ( www.eippharma.com ) ... neflamapimod (previously code named VX-745), with the results ... that demonstrated significant Alzheimer,s disease relevant pharmacological activity.  ... Study 303 (6-week treatment) are the subject of ... (CTAD) scientific conference in San Diego, ...
Breaking Medicine Technology: